Biogen Inc logo

BIIB - Biogen Inc Share Price

$306.72 7.1  2.4%

Last Trade - 05/06/20

Sector
Healthcare
Size
Large Cap
Market Cap £40.23bn
Enterprise Value £41.88bn
Revenue £11.39bn
Position in Universe 196th / 6325
Bullish
Bearish
Unlock BIIB Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Biogen Inc revenues increased 1% to $3.53B. Net income decreased 1% to $1.4B. Revenues reflect Rest of World segment increase of 13% to $998.1M, United States segment increase of 5% to $1.58B. Net income was offset by FV Adjustments of Financial Investments decrease from $290.8M (income) to $60.9M (expense), Gain (loss) on sales of investment decrease from $85.6M (income) to $16.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BIIB Revenue Unlock BIIB Revenue

Net Income

BIIB Net Income Unlock BIIB Revenue

Normalised EPS

BIIB Normalised EPS Unlock BIIB Revenue

PE Ratio Range

BIIB PE Ratio Range Unlock BIIB Revenue

Dividend Yield Range

BIIB Dividend Yield Range Unlock BIIB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BIIB EPS Forecasts Unlock BIIB Revenue
Profile Summary

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated April 1, 1997
Public Since September 17, 1991
No. of Shareholders: 540
No. of Employees: 7,400
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Global 100, Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 166,087,172
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BIIB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BIIB
Upcoming Events for BIIB
Monday 8th June, 2020
Biogen Inc at Biotechnology Industry Organization (BIO) International Convention (Virtual)
Thursday 18th June, 2020 Estimate
Biogen Inc Annual Shareholders Meeting
Tuesday 21st July, 2020 Estimate
Q2 2020 Biogen Inc Earnings Release
Tuesday 20th October, 2020 Estimate
Q3 2020 Biogen Inc Earnings Release
Frequently Asked Questions for Biogen Inc
What is the Biogen Inc share price?

As of 05/06/20, shares in Biogen Inc are trading at $306.72, giving the company a market capitalisation of £40.23bn. This share price information is delayed by 15 minutes.

How has the Biogen Inc share price performed this year?

Shares in Biogen Inc are currently trading at $306.72 and the price has moved by 36.71% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biogen Inc price has moved by 26.22% over the past year.

What are the analyst and broker recommendations for Biogen Inc?

Of the analysts with advisory recommendations for Biogen Inc, there are there are currently 5 "buy" , 18 "hold" and 2 "sell" recommendations. The overall consensus recommendation for Biogen Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Biogen Inc next release its financial results?

Biogen Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Biogen Inc dividend yield?

Biogen Inc does not currently pay a dividend.

Does Biogen Inc pay a dividend?

Biogen Inc does not currently pay a dividend.

When does Biogen Inc next pay dividends?

Biogen Inc does not currently pay a dividend.

How do I buy Biogen Inc shares?

To buy shares in Biogen Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biogen Inc?

Shares in Biogen Inc are currently trading at $306.72, giving the company a market capitalisation of £40.23bn.

Where are Biogen Inc shares listed? Where are Biogen Inc shares listed?

Here are the trading details for Biogen Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BIIB
What kind of share is Biogen Inc?

Based on an overall assessment of its quality, value and momentum, Biogen Inc is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Biogen Inc share price forecast 2020?

Shares in Biogen Inc are currently priced at $306.72. At that level they are trading at 5.13% discount to the analyst consensus target price of 0.00.

Analysts covering Biogen Inc currently have a consensus Earnings Per Share (EPS) forecast of 33.005 for the next financial year.

How can I tell whether the Biogen Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biogen Inc. Over the past six months, the relative strength of its shares against the market has been 2.93%. At the current price of $306.72, shares in Biogen Inc are trading at 7.1% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biogen Inc PE Ratio?

The Biogen Inc PE ratio based on its reported earnings over the past 12 months is 9.13. The shares are currently trading at $306.72.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Biogen Inc?

Biogen Inc's management team is headed by:

Michel Vounatsos - CEO
Stelios Papadopoulos - CHM
Ginger Gregory - CHO
Chirfi Guindo - EVP
Jeffrey Capello - CFO
Susan Alexander - EVP
Daniel Karp - EVP
Alexander Denner - IND
Alfred Sandrock - EVP
Robin Kramer - CAO
Caroline Dorsa - IND
Nancy Leaming - IND
William Hawkins - IND
Jesus Mantas - IND
Alphonse Galdes - EVP
Who are the major shareholders of Biogen Inc?

Here are the top five shareholders of Biogen Inc based on the size of their shareholding:

PRIMECAP Management Company Investment Advisor
Percentage owned: 9.61% (16.0m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.57% (14.2m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.28% (10.4m shares)
Vanguard PRIMECAP Fund Mutual Fund
Percentage owned: 5.56% (9.23m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 4.97% (8.26m shares)
Similar to BIIB
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.